In Brief: Qmed
This article was originally published in The Gray Sheet
Qmed: Appoints Howard Waltham as chairman of the board, replacing company founder Michael Cox, who will continue as Qmed president and CEO. From 1985 to 1995, Waltham served as chairman and CEO of Sanus Corp. Health System, a national HMO company. In early May, Qmed finalized a strategic alliance with SmithKline Beecham under which SKB obtained exclusive rights to market and sell Qmed's ohms/cad (on-line health management system for coronary artery disease) to U.S. managed care companies in return for an equity investment -- 177,777 shares of Qmed common stock at $11.25 per share -- from SKB's venture capital affiliate S.R. One, Ltd. S.R. One also obtained a warrant to acquire an additional 63,492 shares of Qmed common at $15.75 per share...
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.